Principal Financial Group
RYTM icon

Principal Financial Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Principal Financial Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Sell
4,220
-1,417
-25% -$128K ﹤0.01% 2007
2026
Q1 		$490K Sell
5,637
-561
-9% -$54.6K ﹤0.01% 2024
2025
Q4 		$663K Sell
6,198
-6,400
-51% -$679K ﹤0.01% 2017
2025
Q3 		$1.27M Sell
12,598
-469
-4% -$43.5K ﹤0.01% 1891
2025
Q2 		$826K Sell
13,067
-24,089
-65% -$1.47M ﹤0.01% 1919
2025
Q1 		$1.97M Buy
37,156
+272
+0.7% +$15.1K ﹤0.01% 1773
2024
Q4 		$2.06M Buy
36,884
+4,298
+13% +$237K ﹤0.01% 1793
2024
Q3 		$1.71M Buy
32,586
+23,054
+242% +$1.1M ﹤0.01% 1789
2024
Q2 		$391K Buy
9,532
+2,352
+33% +$93.9K ﹤0.01% 2009
2024
Q1 		$311K Buy
7,180
+1,227
+21% +$53.7K ﹤0.01% 2079
2023
Q4 		$274K Buy
+5,953
New +$188K ﹤0.01% 2087
2021
Q3 		– Sell
-11,364
Closed -$223K – 2615
2021
Q2 		$223K Buy
11,364
+1,562
+16% +$32.4K ﹤0.01% 2444
2021
Q1 		$208K Sell
9,802
-8,000
-45% -$232K ﹤0.01% 2375
2020
Q4 		$529K Buy
+17,802
New +$452K ﹤0.01% 2097
2020
Q3 		– Sell
-9,377
Closed -$209K – 2351
2020
Q2 		$209K Buy
+9,377
New +$183K ﹤0.01% 2179

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group's RYTM Position: Q2 2026 in Review

Principal Financial Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 25% in Q2 2026, selling an estimated $128K and leaving 4,220 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

Principal Financial Group first reported a position in RYTM in Q2 2020 and has held it in 15 quarters since. The position peaked at $2.06M in Q4 2024. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Principal Financial Group held 4,220 shares of Rhythm Pharmaceuticals worth $469K as of Q2 2026.
  • Principal Financial Group sold 1,417 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2007 holding.
  • Principal Financial Group first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • Principal Financial Group's Rhythm Pharmaceuticals position peaked at $2.06M in Q4 2024.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.